Emerging therapeutics for advanced thyroid malignancies: Rationale and targeted approaches

Expert Opinion on Investigational Drugs

Volumn 20, Issue 10, 2011, Pages 1357-1375

  Harris, Pamela Jo ^a   Bible, Keith C ^b  

^a NATIONAL CANCER INSTITUTE   (United States)

^b MAYO CLINIC   (United States)

Author keywords

Anaplastic thyroid cancer; Differentiated thyroid cancer; Medullary thyroid cancer; Taxanes; Tyrosine kinase inhibitors

Indexed keywords

AG 01376; ALKYLATING AGENT; ANGIOGENESIS INHIBITOR; ANTHRACYCLINE DERIVATIVE; ANTIMETABOLITE; ANTIMITOTIC AGENT; AXITINIB; AZD 1839; CANCER VACCINE; CARBOZANTINIB; CETUXIMAB; DNA TOPOISOMERASE INHIBITOR; ERLOTINIB; EVEROLIMUS; GEFITINIB; HEAT SHOCK PROTEIN 90 INHIBITOR; HISTONE DEACETYLASE INHIBITOR; IMMUNOMODULATING AGENT; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; MOTESANIB; PAZOPANIB; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; PHOSPHOTRANSFERASE INHIBITOR; PROTEASOME INHIBITOR; RO 5185426; SELUMETINIB; SORAFENIB; SUNITINIB; TEMSIROLIMUS; UNCLASSIFIED DRUG; UNINDEXED DRUG; VANDETANIB; VEMURAFENIB; XL 281;

ABDOMINAL PAIN; ACANTHOSIS; ADVANCED CANCER; ANAPLASTIC THYROID CANCER; ANEMIA; ANTINEOPLASTIC ACTIVITY; ARTHRALGIA; ASTHENIA; BLEEDING; BLURRED VISION; CANCER CHEMOTHERAPY; CANCER CLASSIFICATION; CANCER SURVIVAL; CARDIOTOXICITY; COUGHING; DIARRHEA; DIFFERENTIATED THYROID CANCER; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG ERUPTION; DRUG TOLERABILITY; DYSPNEA; FATIGUE; HAND FOOT SYNDROME; HISTOPATHOLOGY; HUMAN; HURTHLE CELL THYROID CANCER; HYPERGLYCEMIA; HYPERTENSION; HYPOPHOSPHATEMIA; HYPOPIGMENTATION; INTENSITY MODULATED RADIATION THERAPY; KERATOACANTHOSIS; LYMPHOCYTOPENIA; MELANOMA; METASTASIS; MUCOSA INFLAMMATION; MUSCULOSKELETAL PAIN; NAUSEA; NAUSEA AND VOMITING; NEUTROPENIA; NONHUMAN; PERIPHERAL EDEMA; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PROGRESSION FREE SURVIVAL; QT PROLONGATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SIDE EFFECT; SIGNAL TRANSDUCTION; SKIN CARCINOMA; SQUAMOUS CELL CARCINOMA; STOMATITIS; THORAX PAIN; THYROID CANCER; THYROID FOLLICLE CELL; THYROID FOLLICULAR CARCINOMA; THYROID MEDULLARY CARCINOMA; THYROID PAPILLARY CARCINOMA; VOMITING; WEIGHT REDUCTION;

ANTINEOPLASTIC AGENTS; CARCINOMA, MEDULLARY; DISEASE PROGRESSION; HUMANS; MOLECULAR TARGETED THERAPY; THYROID NEOPLASMS;

EID: 80052784382     PISSN: 13543784     EISSN: 17447658     Source Type: Journal    
DOI: 10.1517/13543784.2011.614230     Document Type: Review

References (95)

1. Cancer Facts and Figures 2009
2. Chen AY, Jemal A, Ward EM. Increasing incidence of differentiated thyroid cancer in the United States, 1988-2005. Cancer 2009;115:3801-7
3. Enewold L, Zhu K, Ron E, et al. Rising thyroid cancer incidence in the United States by demographic and tumor characteristics, 1980-2005. Cancer Epidemiol Biomarkers Prev 2009;18:784-91
4. Hayat MJ, Howlader N, Reichman ME, Edwards BK. Cancer statistics, trends, and multiple primary cancer analyses from the Surveillance, Epidemiology, and End Results (SEER) Program. Oncologist 2007;12:20-37 (Pubitemid 46143500)
5. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2009. CA Cancer J Clin 2009;59:225-49
6. Al-Eid HS, Omer S. Cancer Incidence Report Saudi Arabia. Kingdom of Saudi Arabia Ministry of Health Saudi Cancer Registry. 2003
7. McIver B, Hay ID, Giuffrida DF, et al. Anaplastic thyroid carcinoma: a 50-year experience at a single institution. Surgery 2001;130:1028-34 (Pubitemid 34014569)
8. Smallridge RC, Copland JA. Anaplastic thyroid carcinoma: pathogenesis and emerging therapies. Clinical Oncol (R Coll Radiol) 2010;22:486-97
9. Nikiforov YE. Thyroid carcinoma: molecular pathways and therapeutic targets. Mod Pathol 2008;21(Suppl 2):S37-43 (Pubitemid 351592770)
10. Rodriguez-Antona C, Pallares J, Montero-Conde C, et al. Overexpression and activation of EGFR and VEGFR2 in medullary thyroid carcinomas is related to metastasis. Endocr Relat Cancer 2010;17:7-16
11. Schiff BA, McMurphy AB, Jasser SA, et al. Epidermal growth factor receptor (EGFR) is overexpressed in anaplastic thyroid cancer, and the EGFR inhibitor gefitinib inhibits the growth of anaplastic thyroid cancer. Clin Cancer Res 2004;10:8594-602 (Pubitemid 40053427)
12. Smallridge RC, Marlow LA, Copland JA. Anaplastic thyroid cancer: molecular pathogenesis and emerging therapies. Endocr Relat Cancer 2009;16:17-44
13. Todaro M, Iovino F, Eterno V, et al. Tumorigenic and metastatic activity of human thyroid cancer stem cells. Cancer Res 2010;70:8874-85
14. Hoffmann S, Maschuw K, Hassan I, et al. Functional thyrotropin receptor attenuates malignant phenotype of follicular thyroid cancer cells. Endocrine 2006;30:129-38 (Pubitemid 46020339)
15. Spitzweg C, Baker CH, Bergert ER, et al. Image-guided radioiodide therapy of medullary thyroid cancer after carcinoembryonic antigen promoter-targeted sodium iodide symporter gene expression. Hum Gene Ther 2007;18:916-24 (Pubitemid 47587318)
16. Myers RM, Greiner SM, Harvey ME, et al. Preclinical pharmacology and toxicology of intravenous MV-NIS, an oncolytic measles virus administered with or without cyclophosphamide. Clin Pharmacol Ther 2007;82:700-10 (Pubitemid 350114828)
17. Trujillo MA, Oneal MJ, McDonough S, et al. A probasin promoter, conditionally replicating adenovirus that expresses the sodium iodide symporter (NIS) for radiovirotherapy of prostate cancer. Gene Ther 2010;17:1325-32
18. Cohen EE, Rosen LS, Vokes EE, et al. Axitinib is an active treatment for all histologic subtypes of advanced thyroid cancer: results from a phase II study. J Clin Oncol 2008;26:4708-13
19. Lucas AS. Phase II study and tissue correlative studies of AZD6244 (ARRY-142886) in iodine-131 refractory papillary thyroid carcinoma (IRPTC) and papillary thyroid carcinoma (PTC) with follicular elements. June 4-8 2010 ASCO Annual Meeting. Chicago, IL, USA.
20. Adjei AA, Cohen RB, Franklin W, et al. Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J Clin Oncol 2008;26:2139-46
21. Chow L. A First in Human Dose-Ranging Study to Assess the Pharmacokinetics, Pharmacodynamics, and Toxicities of the MEK Inhibitor, ARRY-142886 (AZD6244), in Patients with Advanced Solid Malignancies. AACR-NCI-EORTC International Conference on Moledular Targets and Cancer Therapeutics; 2005
22. Sherman SI, Wirth LJ, Droz JP, et al. Motesanib diphosphate in progressive differentiated thyroid cancer. N Engl J Med 2008;359:31-42 (Pubitemid 351931094)
23. Schlumberger MJ, Elisei R, Bastholt L, et al. Phase II study of safety and efficacy of motesanib in patients with progressive or symptomatic, advanced or metastatic medullary thyroid cancer. J Clin Oncol 2009;27:3794-801
24. Bible KC, Suman VJ, Molina JR, et al. Efficacy of pazopanib in progressive, radioiodine-refractory, metastatic differentiated thyroid cancers: results of a phase 2 consortium study. Lancet Oncol 2010;11:962-72.
25. Sideras K, Menefee ME, Burton JK, et al. Profound hair and skin hypopigmentation in an African American woman treated with the multi-targeted tyrosine kinase inhibitor pazopanib. J Clin Oncol 2010;28:e312-13
26. Flaherty KT, Puzanov I, Kim KB, et al. Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med 2010;363:809-19
27. Kloos RT, Ringel MD, Knopp MV, et al. Phase II trial of sorafenib in metastatic thyroid cancer. J Clin Oncol 2009;27:1675-84.
28. Gupta-Abramson V, Troxel AB, Nellore A, et al. Phase II trial of sorafenib in advanced thyroid cancer. J Clin Oncol 2008;26:4714-19.
29. Hoftijzer H, Heemstra KA, Morreau H, et al. Beneficial effects of sorafenib on tumor progression, but not on radioiodine uptake, in patients with differentiated thyroid carcinoma. Eur J Endocrinol 2009;161:923-31.
30. Lam ET, Ringel MD, Kloos RT, et al. Phase II clinical trial of sorafenib in metastatic medullary thyroid cancer. J Clin Oncol 2010;28:2323-30.
31. Kober F, Hermann M, Handler A, Krotla G. Effect of sorafenib in symptomatic metastatic medullary thyroid cancer. ASCO Annual Meeting 2-5 June 2007. Alexandria, VA, USA.
32. Nagaiah G, Fu P, Wasman J, et al. Phase II trial of sorafenib (bay 43-9006) in patients with advanced anaplastic carcinoma of the thyroid (ATC). May 30-June 2 2009 ASCO Annual Meeting. Orlando, FL, USA
33. Sherman SI. Targeted therapy of thyroid cancer. Biochem Pharmacol 2010;80(5):592-601
34. Chintala L, Kurzrock R, Fu S, et al. Phase I study of tipifarnib and sorafenib in patients with biopsiable advanced cancer (NCI protocol 7156). May 30-June 3 2008 ASCO Annual Meeting. Chicago, IL, USA
35. Hong DS, Cabanillas ME, Wheler J, et al. Inhibition of the Ras/Raf/MEK/ERK and RET kinase pathways with the combination of the multikinase inhibitor sorafenib and the farnesyltransferase inhibitor tipifarnib in medullary and differentiated thyroid malignancies. J Clin Endocrinol Metab 2011;96:997-1005
36. Arnault JP, Wechsler J, Escudier B, et al. Keratoacanthomas and squamous cell carcinomas in patients receiving sorafenib. J Clin Oncol 2009;27:e59-61
37. Smith KJ, Haley H, Hamza S, Skelton HG. Eruptive keratoacanthoma-type squamous cell carcinomas in patients taking sorafenib for the treatment of solid tumors. Dermatol Surg 2009;35:1766-70
38. Cohen E, Needles B, Cullen K, et al. Phase 2 study of sunitinib in refractory thyroid cancer. May 30-June 3 2008 ASCO Annual Meeting. Chicago, IL, USA
39. De Souza J, Busaidy N, Zimrin A, et al. Phase II trial of sunitinib in medullary thryoid cancer (MTC). 2010 ASCO Annual Meeting
40. Ravaud A, de la Fouchardiere C, Courbon F, et al. Sunitinib in patients with refractory advanced thyroid cancer: the THYSU phase II trial. 4-8 June 2008 ASCO Annual Meeting. Chicago, IL, USA
41. Wells SA Jr, Gosnell JE, Gagel RF, et al. Vandetanib for the treatment of patients with locally advanced or metastatic hereditary medullary thyroid cancer. J Clin Oncol 2010;28:767-72.
42. FDA Briefing Document, Oncology Drug Advisory Committee Meeting. 20 July 2010. Silver Spring, MD, USA.
43. Haddad R, Krebs A, Vasselli J, et al. A phase II open-label study of vandetanib in patients with locally advanced or metastatic hereditary medullary thyroid cancer. 2008 ASCO Annual Meeting
44. Wells S, Robinson B, Gagel R, et al. Vandetanib (VAN) in locally advanced or metastatic medullary thyroid cancer (MTC): a randomized, double-blind phase III trial (ZETA). 2010 ASCO Annual Meeting.
45. Kurzrock R, Cohen E, Sherman S, et al. Long-term results in a cohort of medullary thyroid cancer (MTC) patients (pts) in a phase I study of XL184 (BMS 907351), an oral inhibitor of MET, VEGFR2, and RET. 4-8 June 2010 ASCO Annual Meeting. Chicago, IL, USA.
46. D'Amato RJ, Loughnan MS, Flynn E, Folkman J. Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci USA 1994;91:4082-5 (Pubitemid 24139577)
47. Ain KB, Lee C, Williams KD. Phase II trial of thalidomide for therapy of radioiodine-unresponsive and rapidly progressive thyroid carcinomas. Thyroid 2007;17:663-70 (Pubitemid 47311556)
48. Ain K, Lee C, Holbrook K, et al. Phase II study of lenalidomide in distantly metastatic, rapidly progressive, and radioiodine-unresponsive thyroid carcinomas: preliminary results. 4-8 June 2008 ASCO Annual Meeting. Chicago, IL, USA
49. Catalano MG, Fortunati N, Pugliese M, et al. Valproic acid induces apoptosis and cell cycle arrest in poorly differentiated thyroid cancer cells. J Clin Endocrinol Metab 2005;90:1383-9 (Pubitemid 40463993)
50. Fortunati N, Catalano MG, Arena K, et al. Valproic acid induces the expression of the Na+/I-symporter and iodine uptake in poorly differentiated thyroid cancer cells. J Clin Endocrinol Metab 2004;89:1006-9 (Pubitemid 38269924)
51. Catalano MG, Poli R, Pugliese M, et al. Valproic acid enhances tubulin acetylation and apoptotic activity of paclitaxel on anaplastic thyroid cancer cell lines. Endocr Relat Cancer 2007;14:839-45 (Pubitemid 350074071)
52. Ringel M, Kloos R, Arbogast D, et al. Phase II study of oral histone deacetylase inhibitor SAHA in patients with metastatic thyroid cancer. 77th Annual Meeting of the American Thyroid Association; 2006. Phoenix, AZ
53. Piekarz R, Luchenko V, Draper D, et al. Phase I trial of romidepsin, a histone deacetylase inhibitor, given on days one, three and five in patients with thyroid and other advanced cancers. 30 May-3 June 2008 ASCO Annual Meeting. Chicago, IL, USA
54. Sherman E, Fury M, Tuttle R, et al. Phase II study of depsipeptide (DEP) in radioiodine (RAI)-refractory metastatic nonmedullary thryoid carcinoma. 2009 ASCO Annual Meeting
55. Catalano MG, Pugliese M, Gargantini E, et al. Cytotoxic activity of the histone deacetylase inhibitor panobinostat (LBH589) in anaplastic thyroid cancer in vitro and in vivo. Int J Cancer 2011; [Epub ahead of print]
56. LaBonte MJ, Wilson PM, Fazzone W, et al. DNA microarray profiling of genes differentially regulated by the histone deacetylase inhibitors vorinostat and LBH589 in colon cancer cell lines. BMC Med Genomics 2009;2:67
57. Jaskula-Sztul R, Pisarnturakit P, Landowski M, et al. Expression of the active notch1 decreases MTC tumor growth in vivo. J Surg Res 2011; [Epub ahead of print]
58. Beck J, Fischer T, Rowinsky E, et al. Phase I pharmacokinetic (PK) and pharmacodynamic (PD) study of LBH589A: A novel histone deacetylase inhibitor. 5-8 June 2004 ASCO Annual Meeting. New Orleans, LA, USA
59. Venkataraman GM, Yatin M, Marcinek R, Ain KB. Restoration of iodide uptake in dedifferentiated thyroid carcinoma: relationship to human Na+/I-symporter gene methylation status. J Clin Endocrinol Metab 1999;84:2449-57
60. Ohta K, Endo T, Haraguchi K, et al. Ligands for peroxisome proliferator-activated receptor gamma inhibit growth and induce apoptosis of human papillary thyroid carcinoma cells. J Clin Endocrinol Metab 2001;86:2170-7 (Pubitemid 32472935)
61. Copland JA, Marlow LA, Kurakata S, et al. Novel high-affinity PPARgamma agonist alone and in combination with paclitaxel inhibits human anaplastic thyroid carcinoma tumor growth via p21WAF1/CIP1. Oncogene 2006;25:2304-17
62. Kebebew E, Peng M, Reiff E, et al. A phase II trial of rosiglitazone in patients with thyroglobulin-positive and radioiodine-negative differentiated thyroid cancer. Surgery 2006;140:960-6; discussion 6-7
63. Smallridge R, Copland J, Brose M, et al. Phase I study of CS-7017, an oral PPAR-g agonist, in combination with paclitaxel in advanced anaplastic thyroid cancer. AACR 102nd Annual Meeting; 2011. Orlando, FL
64. Handkiewicz-Junak D, Roskosz J, Hasse-Lazar K, et al. 13-cis-retinoic acid re-differentiation therapy and recombinant human thyrotropin-aided radioiodine treatment of non-Functional metastatic thyroid cancer: a single-center, 53-patient phase 2 study. Thyroid Res 2009;2(1):8
65. Coelho SM, Vaisman F, Buescu A, et al. Follow-up of patients treated with retinoic acid for the control of radioiodine non-responsive advanced thyroid carcinoma. Braz J Med Biol Res 2011;44:73-7
66. Hoffmann S, Rockenstein A, Ramaswamy A, et al. Retinoic acid inhibits angiogenesis and tumor growth of thyroid cancer cells. Mol Cell Endocrinol 2007;264:74-81 (Pubitemid 46097303)
67. Liu YY, Stokkel MP, Pereira AM, et al. Bexarotene increases uptake of radioiodide in metastases of differentiated thyroid carcinoma. Eur J Endocrinol 2006;154:525-31
68. Ain KB, Egorin MJ, DeSimone PA. Treatment of anaplastic thyroid carcinoma with paclitaxel: phase 2 trial using ninety-six-hour infusion. Collaborative Anaplastic Thyroid Cancer Health Intervention Trials (CATCHIT) Group. Thyroid 2000;10:587-94. (Pubitemid 30670619)
69. Kawada K, Kitagawa K, Kamei S, et al. The feasibility study of docetaxel in patients with anaplastic thyroid cancer. Jpn J Clin Oncol 2010;40:596-9
70. Troch M, Koperek O, Scheuba C, et al. High efficacy of concomitant treatment of undifferentiated (anaplastic) thyroid cancer with radiation and docetaxel. J Clin Endocrinol Metab 2010;95:E54-7
71. Foote RL, Molina JR, Kasperbauer JL, et al. Enhanced survival in locoregionally confined anaplastic thyroid carcinoma: a single-institution experience using aggressive multimodal therapy. Thyroid 2011;21:25-30
72. Fury MG, Solit DB, Su YB, et al. A phase I trial of intermittent high-dose gefitinib and fixed-dose docetaxel in patients with advanced solid tumors. Cancer Chemother Pharmacol 2007;59:467-75 (Pubitemid 46122325)
73. Dowlati A, Robertson K, Cooney M, et al. A phase I pharmacokinetic and translational study of the novel vascular targeting agent combretastatin a-4 phosphate on a single-dose intravenous schedule in patients with advanced cancer. Cancer Res 2002;62:3408-16 (Pubitemid 34651387)
74. Mooney CJ, Nagaiah G, Fu P, et al. A phase II trial of fosbretabulin in advanced anaplastic thyroid carcinoma and correlation of baseline serum-soluble intracellular adhesion molecule-1 with outcome. Thyroid 2009;19:233-40
75. Garcia-Rostan G, Costa AM, Pereira-Castro I, et al. Mutation of the PIK3CA gene in anaplastic thyroid cancer. Cancer Res 2005;65:10199-207 (Pubitemid 41743711)
76. Hou P, Liu D, Shan Y, et al. Genetic alterations and their relationship in the phosphatidylinositol 3-kinase/Akt pathway in thyroid cancer. Clin Cancer Res 2007;13:1161-70 (Pubitemid 46424056)
77. Liu Z, Hou P, Ji M, et al. Highly prevalent genetic alterations in receptor tyrosine kinases and phosphatidylinositol 3-kinase/akt and mitogen-activated protein kinase pathways in anaplastic and follicular thyroid cancers. J Clin Endocrinol Metab 2008;93:3106-16
78. Santarpia L, El-Naggar AK, Cote GJ, et al. Phosphatidylinositol 3-kinase/akt and ras/raf-mitogen-activated protein kinase pathway mutations in anaplastic thyroid cancer. J Clin Endocrinol Metab 2008;93:278-84
79. Hou P, Bojdani E, Xing M. Induction of thyroid gene expression and radioiodine uptake in thyroid cancer cells by targeting major signaling pathways. J Clin Endocrinol Metab 2010;95:820-8
80. Jin N, Jiang T, Rosen DM, et al. Dual inhibition of mitogen-activated protein kinase kinase and mammalian target of rapamycin in differentiated and anaplastic thyroid cancer. J Clin Endocrinol Metab 2009;94:4107-12
81. Wu LT, Averbuch SD, Ball DW, et al. Treatment of advanced medullary thyroid carcinoma with a combination of cyclophosphamide, vincristine, and dacarbazine. Cancer 1994;73:432-6 (Pubitemid 24030625)
82. Nocera M, Baudin E, Pellegriti G, et al. Treatment of advanced medullary thyroid cancer with an alternating combination of doxorubicin-streptozocin and 5 FUdacarbazine. Groupe d'Etude des Tumeurs a Calcitonine (GETC). Br J Cancer 2000;83:715-18
83. Argiris A, Agarwala SS, Karamouzis MV, et al. A phase II trial of doxorubicin and interferon alpha 2b in advanced, non-medullary thyroid cancer. Invest New Drugs 2008;26:183-8 (Pubitemid 351357713)
84. Tan AR, Dowlati A, Jones SF, et al. Phase I study of pazopanib in combination with weekly paclitaxel in patients with advanced solid tumors. Oncologist 2010;15:1253-61
85. Alexandre J, Kahatt C, Bertheault-Cvitkovic F, et al. A phase I and pharmacokinetic study of irofulven and capecitabine administered every 2 weeks in patients with advanced solid tumors. Invest New Drugs 2007;25:453-62 (Pubitemid 47222915)
86. Heerschap A, Fiedler W, Marreaud S, et al. A phase I study of NGR-TNF, a novel vascular targeting agent, in patients with refractory solid tumors (EORTC 16041). 2-5 June 2007 ASCO Annual Meeting. Alexandria, VA, USA
87. Gregorc V, Santoro A, Bennicelli E, et al. Phase Ib study of NGR-hTNF, a selective vascular targeting agent, administered at low doses in combination with doxorubicin to patients with advanced solid tumours. Br J Cancer 2009;101:219-24
88. Peled M, Shaish A, Greenberger S, et al. Antiangiogenic systemic gene therapy combined with doxorubicin administration induced caspase 8 and 9-mediated apoptosis in endothelial cells and an anti-metastasis effect. Cancer Gene Ther 2008;15:535-42
89. Braga-Basaria M, Hardy E, Gottfried R, et al. 17-Allylamino-17- demethoxygeldanamycin activity against thyroid cancer cell lines correlates with heat shock protein 90 levels. J Endocrinol Metab 2004;89:2982-8 (Pubitemid 38766397)
90. Marsee DK, Venkateswaran A, Tao H, et al. Inhibition of heat shock protein 90, a novel RET/PTC1-associated protein, increases radioiodide accumulation in thyroid cells. J Biol Chem 2004;279:43990-7 (Pubitemid 39390707)
91. Chatal JF, Campion L, Kraeber-Bodere F, et al. Survival improvement in patients with medullary thyroid carcinoma who undergo pretargeted anti-carcinoembryonic-antigen radioimmunotherapy: a collaborative study with the French Endocrine Tumor Group. J Clin Oncol 2006;24:1705-11 (Pubitemid 46622142)
92. Schott M, Seissler J, Lettmann M, et al. Immunotherapy for medullary thyroid carcinoma by dendritic cell vaccination. J Clin Endocrinol Metab 2001;86:4965-9 (Pubitemid 33020550)
93. Stift A, Sachet M, Yagubian R, et al. Dendritic cell vaccination in medullary thyroid carcinoma. Clin Cancer Res 2004;10:2944-53 (Pubitemid 38619669)
94. Kundra P, Burman KD. Thyroid cancer molecular signaling pathways and use of targeted therapy. Endocrinol Metab Clin North Am 2007;36:839-53; viii (Pubitemid 47126259)
95. Barzon L, Pacenti M, Taccaliti A, et al. A pilot study of combined suicide/cytokine gene therapy in two patients with end-stage anaplastic thyroid carcinoma. J Clin Endocrinol Metab 2005;90:2831-4 (Pubitemid 40686332)